PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...

Sami Corwin has given his Buy rating due to a combination of factors that favor PTC Therapeutics’ market position. The recent FDA approval of Kebilidi, a groundbreaking gene therapy for AADC ...

PTC Therapeutics’ gene therapy, Kebilidi to treat AADC deficiency receives US FDA approval: Warren, New Jersey Friday, November 15, 2024, 10:00 Hrs [IST] PTC Therapeutics, Inc., ...

Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $43 and keeps an Equal Weight rating on the shares. After ...

The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus ...

The Food and Drug Administration (FDA) has granted accelerated approval to Kebilidi™ (eladocagene exuparvovec-tneq) for the treatment of adult and pediatric patients with aromatic L-amino acid ...

At the BioFuture 2024 conference held in New York in November, Seema Kumar, the CEO of Cure, described women’s health as something that has been directed at the “bikini area.” That “bikini” bias ...

Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...

Breakthroughs and Impacts", presented jointly by The Shaw Prize Foundation and the Hong Kong Science Museum, and organised by ...

The DNA synthesis market is growing as demand for DNA synthesis products and services increases across various applications, with significant growth in North America, Europe, and Asia Pacific.Austin, ...

PTC India Ltd., incorporated in the year 1999, is a Small Cap company (having a market cap of Rs 4,930.61 Crore) operating in Power sector. PTC India Ltd. key Products/Revenue Segments include ...